Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Preferred Stock Liabilities: 2019

  • Nurix Therapeutics' Preferred Stock Liabilities was N/A to $48.2 million in Q4 2019 from the same period last year, while for Nov 2019 it was $48.2 million, marking a year-over-year change of. This contributed to the annual value of $48.2 million for FY2019, which is N/A change from last year.
  • As of Q4 2019, Nurix Therapeutics' Preferred Stock Liabilities stood at $48.2 million, which was down 0.00% from $48.2 million recorded in Q3 2019.
  • Nurix Therapeutics' 5-year Preferred Stock Liabilities high stood at $48.2 million for Q3 2019, and its period low was $48.2 million during Q3 2019.
  • In the last 1 years, Nurix Therapeutics' Preferred Stock Liabilities had a median value of $48.2 million in 2019 and averaged $48.2 million.